Aspira Women's Health (AWHL) AI Stock Analysis

• Market Cap: $20.88M
• Dividend Yield: N/A
• Average Volume (3M): 100.39K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.99
• Revenue Growth: 4.17%
• EPS Growth: 68.47%
• Country: US
• Employees: 66
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.13
• Shares Outstanding: 43,480,410
• 10 Day Avg. Volume: 120,018
• 30 Day Avg. Volume: 100,391
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.31
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: $0.49 ▼(-3.00% Downside)

The score is held down primarily by weak financial health (negative equity, ongoing losses, and negative operating cash flow). Technicals are comparatively stronger with an established uptrend, but overbought signals temper the setup. Corporate events are broadly positive yet partly offset by dilution risk, while valuation remains constrained by unprofitability and no dividend.

Positive Factors

AI-powered multi-omic platform

Aspira's OvaSuite AI, multi-omic strategy targets a large, clearly defined addressable market across ovarian risk, adnexal mass triage and endometriosis. If clinical performance and adoption persist, the platform creates durable product differentiation and expansion opportunities across multiple pelvic disease states.

Mayo Clinic laboratory agreement

A multi-year distribution agreement with Mayo Clinic Laboratories materially expands clinical reach and credibility. Long-term non-exclusive placement in Mayo's catalog can drive sustained test volume, referral flows and reimbursement visibility, strengthening Aspira's commercial footprint and access to physician networks.

Flexible equity financing access

The $10M flexible equity facility provides a structural liquidity option without covenants, extending runway and funding operations or commercialization activities. While dilutive when used, the on-demand nature gives management durable optionality to support execution without immediate debt or restrictive covenants.

Negative Factors

Negative shareholders' equity

Negative stockholders' equity is a structural solvency signal: liabilities exceed assets. This limits financial flexibility, raises creditor risk and can constrain strategic options like M&A or large commercial investments unless equity is restored, pressuring long-term capital stability if not remedied.

Consistently negative operating cash flow

Persistent negative operating cash flow means the business does not self-fund growth and must continually access external capital. Over months to years this stresses dilution risk, increases dependency on financings, and can curtail investment in sales, R&D or commercialization if new funding becomes costlier.

Ongoing unprofitability and high operating losses

Material operating losses reflect a structural gap between revenues and cost base. Even with improved gross margins, persistent negative EBIT requires either sustained revenue scale or operating expense reductions to reach breakeven; otherwise profitability risk persists and limits self-sustaining growth.

Aspira Women's Health Business Overview & Revenue Model

Company Description

Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, the company operates Aspira Synergy, a testing platform and cloud service for decentralized access of protein biomarker and hereditary genetic testing; and owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, its pipeline products include OVAWatch, EndoCheck, and OVAInherit. The company serves physicians, physician office laboratories, and national and regional laboratories. It has a collaborative research agreement with Baylor Genetics; an agreement with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is headquartered in Austin, Texas.

How the Company Makes Money

Aspira Women's Health generates revenue primarily through the sale of its diagnostic tests, such as OVA1 and Overa, to healthcare providers, hospitals, and laboratories. The company operates on a fee-for-service model, where they charge for each test performed. In addition, AWHL may benefit from reimbursement agreements with insurance companies, allowing healthcare providers to receive compensation for the tests administered to patients. Strategic partnerships with healthcare institutions and collaborations with research organizations also contribute to revenue growth, as they can expand market access and validate the efficacy of AWHL's products. Furthermore, the company may explore opportunities in government grants or funding related to women's health initiatives, further diversifying its income streams.

Aspira Women's Health Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Aspira Women's Health Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AWHL, the sentiment is Positive. The current price of 0.5 is below the 20-day moving average (MA) of 0.53, above the 50-day MA of 0.47, and above the 200-day MA of 0.33, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 48.08 is Neutral, neither overbought nor oversold. The STOCH value of 59.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AWHL.

Aspira Women's Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRPO	56 Neutral	$42.99M	-29.40	-9.76%	―	30.95%	59.67%
BDSX	52 Neutral	$80.91M	-1.90	-302.55%	―	22.29%	31.93%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AWHL	48 Neutral	$20.88M	-1.27	―	―	4.17%	68.47%
MYNZ	48 Neutral	$10.78M	―	―	―	―	―
VNRX	47 Neutral	$37.33M	-1.25	―	―	14.48%	36.83%
TRIB	46 Neutral	$15.21M	-0.35	―	―	-4.35%	-6.31%

Aspira Women's Health Corporate Events

Aspira Women’s Health Secures New Subordinated Term Loan

On January 30, 2026, Aspira Women’s Health Inc. entered into a Subordinated Business Loan and Security Agreement with Agile Lending, LLC as lead lender and Agile Capital Funding, LLC as collateral agent, under which the lenders provided a $1,050,000 secured term loan to Aspira and certain subsidiaries, evidenced by a subordinated secured promissory note bearing approximately $441,000 in interest if paid on schedule and maturing on August 26, 2026, with the proceeds designated for general corporate purposes. The loan is subordinated to all senior indebtedness and secured by a continuing security interest in substantially all of the company’s and co-borrowers’ personal property, is subject to customary affirmative and negative covenants and specified events of default that could allow acceleration and collateral repossession, and reflects Aspira’s ongoing effort to access additional financing while accepting tighter creditor protections and potential risks for stakeholders in the event of financial stress or covenant breaches.

The most recent analyst rating on (AWHL) stock is a Hold with a $0.45 price target. To see the full list of analyst forecasts on Aspira Women’s Health stock, see the AWHL Stock Forecast page.

Aspira Women’s Health Showcases AI Ovarian Diagnostics Platform

On December 29, 2025, Aspira Women’s Health published a new investor presentation outlining how its AI-powered, multi-omic diagnostic platform targets a more than 10.5 million–patient addressable market across ovarian cancer risk assessment, adnexal mass triage and endometriosis risk. The deck highlights clinical data showing that the OvaSuite portfolio, including Ova1, Ova1Plus and OvaWatch, can detect malignancy risk that traditional CA-125 testing often misses, improve triage of women with indeterminate adnexal masses and potentially cut unnecessary surgeries in the United States, thereby positioning Aspira to capture greater share in gynecologic diagnostics while it advances a pipeline aimed at improving outcomes and reducing disparities for women across multiple pelvic disease states.

The most recent analyst rating on (AWHL) stock is a Hold with a $0.49 price target. To see the full list of analyst forecasts on Aspira Women’s Health stock, see the AWHL Stock Forecast page.

Aspira Women’s Health secures flexible equity financing agreement

On December 23, 2025, Aspira Women’s Health Inc. entered into a purchase agreement with institutional investor Lincoln Park Capital Fund, LLC that allows the company, at its discretion, to sell up to $10 million of its common stock over a 24‑month period, subject to certain pricing, volume and ownership caps. The structure gives Aspira flexible, on-demand access to equity financing without financial covenants or use‑of‑proceeds restrictions, while limiting Lincoln Park’s ownership stake and prohibiting short selling, and may help the company bolster its balance sheet and liquidity, although it also introduces potential future dilution for existing shareholders as shares are issued under the program.

The most recent analyst rating on (AWHL) stock is a Sell with a $0.37 price target. To see the full list of analyst forecasts on Aspira Women’s Health stock, see the AWHL Stock Forecast page.

Aspira Women’s Health Expands Reach via Mayo Clinic Partnership

On December 16, 2025, Aspira Women’s Health entered into a five-year Laboratory Services Agreement with Mayo Collaborative Services, doing business as Mayo Clinic Laboratories, under which Aspira will supply its Ova1Plus and OvaWatch tests to Mayo on a non-exclusive, as-requested basis for clinical use. Mayo will add Aspira’s tests to its catalog, manage ordering, results delivery and billing, while Aspira invoices Mayo at fixed fees during the initial term, a structure that expands Aspira’s clinical reach through Mayo’s network and could strengthen its market position in ovarian cancer risk assessment diagnostics without exclusivity constraints.

The most recent analyst rating on (AWHL) stock is a Sell with a $0.37 price target. To see the full list of analyst forecasts on Aspira Women’s Health stock, see the AWHL Stock Forecast page.